Ready to explore your next step
For type 2 diabetes , NICE guideline NG28 recommends considering GLP-1 agonists as an option when: Triple therapy with metformin and two other oral drugs is ineffective, not tolerated, or contraindicated The person has a BMI 35 kg/m (or 32.5 kg/m in people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity Insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities Treatment should be continued only if there is a beneficial metabolic response (HbA1c reduction of at least 11 mmol/mol [1.0%] and weight loss of at least 3% of initial body weight at 6 months)
These are topline figures from the company, not the full published data, and retatrutide isnt approved anywhere yet
Headache medication might help with the pain, but speak to a medical professional beforehand to ensure it is safe to take with a GLP-1 medication
However, if you notice severe swelling, redness extending beyond 2 inches, fever, or trouble breathing, reach out to a healthcare provider right away
Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial
